Mixed‐Genotype <scp>HCV</scp> Direct Acting Antiviral Outcomes: A <scp>CANUHC</scp> Analysis-Reference-Cited by-同舟云学术

Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis

Published:2024-08-12 Issue: Volume: Page:
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:Journal of Viral Hepatitis

Author:

Imsirovic Haris¹,Macphail Gisela²,Conway Brian³,Fraser Chris⁴,Borgia Sergio⁵⁶,Smyth Daniel⁷,Wong Alexander⁸,Vachon Marie‐Louise⁹,Webster Duncan⁷,Liu Hongqun²,Feld Jordan¹⁰,Lee Sam²,Cooper Curtis¹¹¹,

Affiliation:

1. Ottawa Hospital Research Institute Ottawa Canada

2. University of Calgary Calgary Canada

3. Vancouver Infectious Diseases Centre Vancouver British Columbia Canada

4. University of Victoria Victoria Canada

5. William Osler Health System, Division of Infectious Diseases Brampton Canada

6. McMaster University Division of Infectious Diseases Hamilton Canada

7. Dalhousie University Halifax Canada

8. University of Saskatchewan Saskatoon Canada

9. Laval University Quebec Canada

10. University of Toronto Toronto Canada

11. University of Ottawa Ottawa Canada

Abstract

ABSTRACTThe prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV‐positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13995

Reference26 articles.

1. Natural History of Chronic Hepatitis C;Seeff L. B.;Hepatology,2002

2. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 310 Diseases and Injuries, 1990‐2015: A Systematic Analysis for the Global Burden of Disease Study 2015;GBD Disease and Injury Incidence and Prevalence Collaborators;Lancet,2016

3. World Health Organization Hepatitis C. accessed May 9 2024 vol: 9 Fact Sheets Web site:https://www.who.int/en/news‐room/fact‐sheets/detail/hepatitis‐c2024.